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A divergent synthetic approach to diverse
molecular scaﬀolds: assessment of lead-likeness
using LLAMA, an open-access computational tool†
Ignacio Colomer,a Christopher J. Empson,ab Philip Craven,ab Zachary Owen,a
Richard G. Doveston,ab Ian Churcher,c Stephen P. Marsden*a and Adam Nelson*ab
Complementary cyclisation reactions of hex-2-ene-1,6-diamine
derivatives were exploited in the synthesis of alternative molecular
scaﬀolds. The value of the synthetic approach was analysed using
LLAMA, an open-access computational tool for assessing the lead-
likeness and novelty of molecular scaﬀolds.
Controlling molecular properties is crucial in drug discovery
because the probability of successful progression is influenced
by parameters including lipophilicity, molecular weight, the
number of aromatic rings and the fraction of sp3-hybridised
carbons (Fsp3).1 As a result, guidelines, such as Lipinski’s rule-
of-five (concerning oral bioavailability),2 have been formulated
to help chemists to target drug-relevant chemical space.3
In turn, controlling the molecular properties of lead com-
pounds is advisable since optimisation generally increases lipo-
philicity, molecular weight and complexity.4 As a result, lead-like
chemical space can be described in terms of both molecular
properties (e.g.5 1o c logPo 3; 14r heavy atomsr 26) and
structural features.5 Unfortunately, most commercially-available
compounds5,6‡ and new synthetic methods5 do not target lead-
like chemical space. The problem is exacerbated when diversity
is considered since chemical space has been explored very unevenly
and unsystematically.7
The challenge5,8 of exploring novel lead-like chemical space
has prompted us6b,9 and others10 to develop lead-oriented syn-
thetic approaches. Demonstrating the value of such approaches
requires tools for virtual library enumeration and evaluation that
are not commonly available within academia. We have therefore
developed LLAMA (Lead-Likeness and Molecular Analysis),§ an
open-access tool that enables decoration11 and assessment of the
lead-likeness of small molecule scaﬀolds (Fig. 1). Each product
is assigned a ‘‘lead-likeness penalty’’ (LLP) which penalises
properties and features that are not lead-like (Fig. 2; ESI†). Rather
than applying strict filters, the penalty increases with deviation
from lead-like space. Scaﬀold novelty is assessed by comparing
the corresponding Murcko assemblies12 (with and without alpha
atoms) with those of, or embedded in, a random 2% of the
‘‘available now’’ set of the ZINC database13 of commercially-
available compounds. Finally, to capture the shape diversity
of the compounds, the principal moments of inertia14a (PMI)
and mean deviation from the plane of best fit14b of low-lying
conformers are determined. To demonstrate LLAMA’s utility,
we analysed the lead-likeness of some scaﬀolds prepared using
an approach that we have developed.
We envisaged a divergent synthetic approach in which unsym-
metrical unsaturated diamine derivatives 1 would be converted
Fig. 1 Graphical representation of the LLAMA workflow. A virtual library is
enumerated by decoration of entered scaﬀolds once or twice using definable
capping reagents and reactions. The lead-likeness, three-dimensionality and
novelty of the virtual library may be analysed.
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into alternative scaﬀolds (Scheme 1). Thus, complementary
cyclisations would yield alternative heterocyclic intermediates 2;
further cyclisation or rearrangement would then yield additional
molecular scaﬀolds 3. The approach would be reminiscent of a
branching pathway approach which enabled a single substrate to
be converted into twelve natural product-like scaﬀolds.15
The fate of the iodocyclisation reactions of hex-2-ene-diamine
derivatives 1 was dependent on the specific protecting groups
used (Scheme 2). Thus, treatment of the diﬀerentially-protected
1a with iodine and sodium bicarbonate in acetonitrile resulted
in cyclisation of the remote Boc-protected amine to yield the
pyrrolidine 4 in 76% yield.16 In stark contrast, under the same
conditions, the doubly Boc-protected amine 1b cyclised through
the allylic carbamate to give a 95 : 5 mixture of the oxazinone
7 and the corresponding oxazolidinone (66% and 4% yield
respectively).17 In each case, regioselectivity was determined
using the diagnostic upfield 13C NMR chemical shift of the
iodine-substituted carbons.
Treatment of the trichloroacetamide 4 with LiHMDS induced
cyclisation to yield the oxazoline 5 which could be hydrolysed to
give the diﬀerentially-protected diamine 6. In contrast, treatment
of the oxazinone 7 with LiHMDS triggered an unexpected rearran-
gement to give the isomeric oxazolidinone 8. Presumably, depro-
tonation of 7 results in participation to yield the corresponding
aziridine 12 which is then ring-opened by iodide (Scheme 3).
Fig. 2 Lead-likeness penalty. Panel A: Graphical representation of con-
tributions to the penalty. Panel B: Penalties for two exemplar compounds.
Scheme 1 Synthetic approach for the conversion of hex-2-ene-1,6-
diamine derivatives 1 into diverse molecular scaﬀolds. Alternative reactive
sites are indicated as coloured circles. Complementary cyclisations would
yield scaﬀolds 2 which might be further cyclised or rearranged to yield
additional scaﬀolds 3.
Scheme 2 Complementary cyclisations onto the central alkene of the
hex-2-ene-1,6-diamine derivatives 1. The specific Ar groups used are shown
in the products.
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The trans configuration of the oxazolidinone 8 was assigned by
the characteristic18 coupling constant (4.5 Hz) between the ring
protons. Although we are unaware of related rearrangements of
oxazinones, aziridines related to the intermediate 12 have been
prepared19 and ring-opened with nucleophiles.20
Palladium-catalysed aminoarylation also enabled cyclisation
onto the central alkene of 1b and the diﬀerentially-protected 1c.
With 5 mol% Pd(OAc)2, 10 mol% BINAP, Cs2CO3 in dioxane at
100 1C,21 cyclisation occurred as expected exclusively through
the distal nitrogen to aﬀord the corresponding pyrrolidines 10a–b
and 11a–b with B85 : 15 diastereoselectivity.
A range of bicyclic scaﬀolds was prepared from the cyclisation
products 6 and 10a (Scheme 4). Thus, Boc-deprotection of 6, and
reaction with CDI, yielded the bicyclic oxazolidinone 13. Similarly,
10a was converted into the related bicyclic scaﬀold 16. Alternatively,
capping of the hydroxyl group of 6 by silylation, followed by Boc
deprotection and LiHMDS-mediated cyclisation yielded the alterna-
tive bicyclic scaﬀold 14. Finally, tBuOK in THF triggered cyclisation of
the hydroxy group of 6 (with displacement of trichloromethyl anion)
Scheme 3 Possible mechanism for the rearrangement of oxazin-2-one 7.
Scheme 4 Synthesis of bicyclic molecular scaﬀolds.
Fig. 3 Evaluation of the molecular scaﬀolds. Panel A: Molecular scaﬀolds
uploaded to LLAMA (Ar1 = 2-imidazole, 2-pyridyl, 2-pyrimidyl or 2-N-methyl-
triazole; Ar2 = 5-pyrimidyl, 4-trifluoromethylphenyl, 3-pyridyl or 3-cyanophenyl).
Panel B: Molecular properties of the enumerated compounds (coloured
according to LLP: 0, green; 3, orange; 6+, red). Panel C: PMI analysis of the
enumerated compounds (red) and centre of gravities for the virtual library
(large blue circle) and 2% of ZINC database (large black circle). Panel D:
Cumulative percentage of molecules within a defined distance of the rod-
disc axis for the virtual library (red) and 2% of ZINC database (black) (Panel D).
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to yield the oxazolidinone 15; similar cyclisations22 have been
previously reported.
Overall, six diverse scaﬀolds were therefore prepared from
the diﬀerentially-protected diamines 1. LLAMA was used to
assess the value of the scaﬀolds 17–22 (Fig. 3). In each case,
the enumerated library comprised compounds that had been
decorated once or twice with exemplar medicinal chemistry
capping groups.¶
Our approach yielded scaﬀolds that allow significant lead-like
chemical space to be explored [average lead-likeness penalty: 1.57
(s = 1.44) for our virtual library cf. 4.17 (s = 3.17) for compounds
from the ZINC database] (Panel B). In addition, the enumerated
compounds are significantly more three-dimensional than a
random 2% of the ZINC database (Panels C and D). Finally, the
novelty assessment showed that the Murcko assembly (without
alpha-atoms) of only one scaﬀolds was known (18 with Ar2 =
4-trifluoromethylphenyl) in the 2% selection of the ZINC data-
base; however, the Murcko assembly with alpha atoms was not
known for this scaﬀold, indicating that its substitution pattern
is novel. We note that LLAMA may also be used prospectively to
design scaﬀolds (e.g. specific Ar2 groups in 19) that are both
novel and lead-like.
In conclusion, our synthetic approach exploited complementary
cyclisations of hex-2-ene-1,6-diamine derivatives to yield a range of
novel, lead-like small molecule scaﬀolds. The computational tool
LLAMA can support the development of lead-oriented synthetic
approaches by enabling assessment of the lead-likeness of alter-
native product scaﬀolds.
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SPM and AN contributed to the scaffold syntheses; CJE, PC, ZO,
RD, IC (Ian Churcher), SPM and AN contributed to the develop-
ment of LLAMA.
Notes and references
‡ The proportion has been estimated to 2.6% (ref. 5), 32% (ref. 6a) and
23% (ref. 6b) depending on the specific criteria and reference set used.
§ LLAMA is available at: https://llama.leeds.ac.uk.
¶ The scaﬀolds 17–19 already contain a variable group (Ar1 or Ar2) and
were subjected to only one further decoration.
1 (a) M. J. Waring, Bioorg. Med. Chem. Lett., 2009, 19, 2844; (b) P. D.
Leeson and B. Springthorpe, Nat. Rev. Drug Discovery, 2007, 6, 881;
(c) T. J. Ritchie and S. J. F. Macdonald, Drug Discovery Today, 2009,
14, 1011; (d) M. C. Wenlock, R. P. Austin, P. Barton, A. M. Davis and
P. D. Leeson, J. Med. Chem., 2003, 46, 1250; (e) F. Lovering, J. Bikker
and C. Humblet, J. Med. Chem., 2009, 52, 6752.
2 (a) C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, Adv.
Drug Delivery Rev., 1997, 23, 3; (b) C. A. Lipinski, Drug Discovery
Today, 2004, 1, 337.
3 A single metric has been developed to estimate drug-likeness by
integrating a number of relevant parameters: G. R. Bickerton,
G. V. Paolini, J. Besnard, S. Muresan and A. L. Hopkins, Nat. Chem.,
2012, 4, 90.
4 (a) T. I. Oprea, A. M. Davis, S. J. Teague and P. D. Leeson, J. Chem. Inf.
Comput. Sci., 2001, 41, 1308; (b) E. Perola, J. Med. Chem., 2010, 53, 2986;
(c) M. M. Hann, Med. Chem. Commun., 2011, 2, 349; (d) G. M. Keseru¨
and G. M. Makara, Nat. Rev. Drug Discovery, 2009, 8, 203.
5 A. Nadin, C. Hattotuwagama and I. Churcher, Angew. Chem., Int. Ed.,
2012, 51, 1114.
6 (a) A. Chuprina, O. Lukin, R. Demoiseaux, A. Buzko and A. Shivanyuk,
J. Chem. Inf. Model., 2010, 50, 470; (b) R. G. Doveston, P. Tosatti,
M. Dow, D. J. Foley, H. Y. Li, A. J. Campbell, D. House, I. Churcher,
S. P. Marsden and A. Nelson, Org. Biomol. Chem., 2015, 13, 859.
7 A. H. Lipkus, Q. Yuan, K. A. Lucas, S. A. Funk, W. F. Bartelt III, R. J.
Schenck and A. J. Trippe, J. Org. Chem., 2008, 73, 4443.
8 (a) P. MacLellan and A. Nelson, Chem. Commun., 2013, 49, 2383;
(b) R. Doveston, S. P. Marsden and A. Nelson, Drug Discovery Today,
2014, 19, 813.
9 (a) D. J. Foley, R. G. Doveston, I. Churcher, A. Nelson and S. P.
Marsden, Chem. Commun., 2015, 51, 11174; (b) T. James, I. Simpson,
J. A. Grant, V. Sridharan and A. Nelson, Org. Lett., 2013, 15, 6094;
(c) T. James, P. MacLellan, G. M. Burslem, I. Simpson, J. A. Grant,
S. Warriner, V. Sridharan and A. Nelson, Org. Biomol. Chem., 2014,
12, 2584.
10 (a) M. Lu¨thy, M. C. Wheldon, C. Haji-Cheteh, M. Atobe, P. S. Bond,
P. O’Brien, R. E. Hubbard and I. J. Fairlamb, Bioorg. Med. Chem.,
2015, 23, 2680; (b) S. V. Ryabukhin, D. M. Panov, D. S. Granat, E. N.
Ostapchuk, D. V. Kryvoruchko and O. O. Grygorenko, ACS Comb.
Sci., 2014, 16, 146; (c) A. Borisov, V. Voloshchuk, M. Nechayev and
O. Grygorenko, Synthesis, 2013, 2413.
11 The default set of capping groups is based on those that we have
used in previous analyses (ref. 6b). See ESI†.
12 G. W. Bemis and M. A. Murcko, J. Med. Chem., 1996, 39, 2887.
13 J. J. Irwin, T. Sterling, M. M. Mysinger, E. S. Bolstad and R. G.
Coleman, J. Chem. Inf. Model., 2012, 52, 1757.
14 (a) W. H. B. Sauer and M. K. Schwarz, J. Chem. Inf. Comput. Sci.,
2003, 43, 987; (b) N. C. Firth, N. Brown and J. Blagg, J. Chem. Inf.
Model., 2012, 52, 2516.
15 D. Robbins, A. F. Newton, C. Gignoux, J.-C. Legeay, A. Sinclair,
M. Rejzek, C. A. Laxon, S. K. Yalamanchili, W. Lewis, M. A. O’Connell
and R. A. Stockman, Chem. Sci., 2011, 2, 2232.
16 For examples of iodocyclisations of N-Boc pentenamines, see:
(a) K. Kamiyama, Y. Urano, S. Kobayashi and M. Ohno, Tetrahedron
Lett., 1987, 28, 3123; (b) S. G. Davies, G. Darren, M. Smyth and
A. Chippindale, J. Chem. Soc., Perkin Trans. 1, 1999, 3089.
17 J. M. Jorda´-Gregori, M. E. Gonza´lez-Rosende, P. Cava-Montesinos,
J. Sepu´lveda-Arques, R. Galeazzi and M. Orena, Tetrahedron: Asym-
metry, 2000, 11, 3769.
18 A. G. Wee and D. D. McLeod, J. Org. Chem., 2003, 68, 6268.
19 For similar rearrangements of g-lactams and cyclic ureas, see:
(a) A. Sudau, W. Mu¨nch, J.-W. Bats and U. Nubbemeyer, Eur. J. Org.
Chem., 2002, 3304; (b) C. Agami, F. Amiot, F. Couty and L. Dechoux,
Tetrahedron Lett., 1998, 39, 5373.
20 For examples for similar aziridines being ring-opening by a range
of nucleophiles, see: (a) A. Padwa, A. C. Flick, C. A. Leverett and
T. Stengel, J. Org. Chem., 2004, 69, 6377; (b) S. Knapp and Y. Yu, Org.
Lett., 2007, 9, 1359.
21 M. B. Bertrand, J. D. Neukom and J. P. Wolfe, J. Org. Chem., 2008,
73, 8851.
22 (a) R. Link, G. Subharekha, M. Gallant, S. J. Danishefsky, T. C. Chou
and L. M. Ballas, J. Am. Chem. Soc., 1996, 118, 2825; (b) K. Stankov,
M. Martinkov, J. Gonda, M. Bago, M. Piltov and G. Go¨nciov, Tetra-
hedron: Asymmetry, 2015, 26, 1394.
Communication ChemComm
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
5 
M
ay
 2
01
6.
 D
ow
nl
oa
de
d 
on
 1
0/
05
/2
01
6 
14
:3
0:
02
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
